ArticleNeoplasia (New York, N.Y.)2014

PACE4-based molecular targeting of prostate cancer using an engineered ⁶⁴Cu-radiolabeled peptide inhibitor.

Frédéric Couture et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.